US Patent Issued to bioAffinity Technologies on Feb. 3 for "Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning" (Canadian, American Inventors)

ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,542,215, issued on Feb. 3, was assigned to bioAffinity Technologies Inc. (San Antonio).

"Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning" was invented by Vivienne I. Rebel (San Antonio) and Madeleine E. Lemieux (Plantagenet, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "A system and method for analyzing a sputum sample from a subject suspected of having lung cancer comprising obtaining a plurality of cells from the sputum sample from the subject, marking the plurality of cells with i) a plurality of cell lineage specific marker compositions, ii) a cell viability composition and iii) a tetra (4-ca...